SFT2D2 and prostate carcinoma: Among the 48 chimeric RNAs mentioned, AGREP analysis (https://www.tgries.de/agrep/) was performed to quantify their expression by searching for specific junction sequences in the CPGEA RNA‐seq data, as described in our previous study.[8] Only SFT2D2‐TBX19 and ERV3‐1‐ZNF506 were associated with poor prognosis of prostate cancer patients (Figure 1C and Figure S1C, Supporting Information).